Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Pharmaceutical Preparations · Tel Aviv · filing with the SEC since 1996
Grade5.8
◀ Past 5.9● Present 6.3▶ Future 4.9
Who owns Teva Pharmaceutical Industries Limited
As filed with the SECHolders of 5% or more
4
Harel Insurance Investments & Financial Services Ltd holds 6.3% of Ordinary Shares, par value NIS 0.10 per share, as its SCHEDULE 13G/A filed Feb 9, 2026 says.
Directors and officers
23
report now, of 48 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Harel Insurance Investments & Financial Services Ltd
SCHEDULE 13G/A · filed Feb 9, 2026 · Ordinary Shares, par value NIS 0.10 per share · 5.1% in Oct 6, 2025
Migdal Insurance & Financial Holdings Ltd
SCHEDULE 13G · filed Feb 17, 2026 · Ordinary Shares, par value NIS 0.01 per share
Phoenix Financial Ltd.
SCHEDULE 13G · filed Jul 22, 2025 · Ordinary Shares, par value NIS 0.10 per share
Menora Mivtachim Holdings Ltd
SCHEDULE 13G · filed Jul 17, 2025 · Ordinary Shares, par value NIS 0.10 per share
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · COMMON STOCK · reported falling below 5%, from 5.1% in Aug 6, 2025
What TEVA reports owning in othersstakes of 5% or more, and other ties
27 subsidiaries in 17 countries, from the list filed with the 10-K filed Feb 3, 2026.
Insider tradesForm 4
66sales
0purchases
32sales on a scheduled plan
15people selling
$126Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window15 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Francis Richard D | President and CEO | 8 | $41.8M | 8 | 0 | $0 |
| Kalif Eliyahu Sharon | EVP, Chief Financial Officer | 3 | $20.7M | 3 | 0 | $0 |
| Mignone Roberto | director | 3 | $18.0M | 0 | 0 | $0 |
| Sabag Mark | See "Remarks" | 6 | $17.0M | 0 | 0 | $0 |
| Daniell Richard | EVP, Europe Commercial | 10 | $14.0M | 6 | 0 | $0 |
| Hughes Eric A | "See ""Remarks""" | 5 | $4.2M | 5 | 0 | $0 |
| Fox Christine | EVP, U.S. Commercial | 5 | $2.7M | 3 | 0 | $0 |
| Lippman Evan | EVP, Business Development | 3 | $2.2M | 3 | 0 | $0 |
| Weiss Amir | Chief Accounting Officer | 7 | $1.9M | 0 | 0 | $0 |
| Shields Matthew | EVP, Global Operations | 3 | $1.4M | 2 | 0 | $0 |
| Bergwerk Dov | Interim Chief Legal Officer | 2 | $1.1M | 0 | 0 | $0 |
| Jover Placid | "See ""Remarks""" | 2 | $900,000 | 2 | 0 | $0 |
| Savage Brian | Interim Chief Legal Officer | 7 | $400,000 | 0 | 0 | $0 |
| Satchi-Fainaro Ronit | director | 1 | $0 | 0 | 0 | $0 |
| Zaks Tal Zvi | director | 1 | $0 | 0 | 0 | $0 |